|
시장보고서
상품코드
2050701
털세포 백혈병 시장 : 치료법별, 투여 경로별, 연령층별, 성별 유형별, 최종사용자별, 유통 채널별, 지역별Hairy Cell Leukemia Market, By Therapy Type, By Route of Administration, By Age Group, By Gender, By End User, By Distribution Channel, By Region |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
털세포 백혈병 시장은 2026년에 1억 5,250만 달러로 추정되고, 2033년까지 2억 4,170만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 6.8%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 1억 5,250만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 6.80% | 2033년 시장 규모 예측 : | 2억 4,170만 달러 |
세계 털세포 백혈병 시장은 최근 유병률 증가, 진단 기술 발전, 혁신적인 치료법 개발에 힘입어 최근 몇 년 동안 괄목할 만한 성장세를 보이고 있습니다. 털세포 백혈병은 백혈구의 일종인 B림프구에 영향을 미치는 희귀하고 만성적이며 진행이 느린 혈액암의 일종입니다. 이 질환은 골수, 혈액, 비장에 비정상적인 털세포가 존재하는 것이 특징이며, 피로, 잦은 감염, 비장 비대 등의 증상을 유발합니다. 이 질환에 대한 인식이 높아지고 효과적인 치료법이 보급됨에 따라 세계 털세포 백혈병 시장은 예측 기간 동안 상당한 성장을 이룰 것으로 예측됩니다.
시장 역학:
세계 털세포 백혈병 시장은 촉진요인, 억제요인, 기회 등 여러 요인의 영향을 받습니다. 시장의 주요 촉진요인 중 하나는 유전적 소인, 환경적 요인, 고령화 등의 요인에 기인하는 전 세계 털세포 백혈병 발병률 증가입니다. 또한, 유세포 분석 및 면역조직화학과 같은 진단 기술의 발전으로 이 질환의 검출 및 진단이 개선되어 시장 성장을 더욱 촉진하고 있습니다. 그러나 높은 치료비, 개발도상국에서의 낮은 인식, 화학요법 및 표적치료제에 따른 부작용 등의 요인으로 인해 시장 성장이 제한될 수 있습니다. 이러한 과제에도 불구하고, 신규 표적치료제 개발, 제약사와 연구기관 간 협력 강화, 신흥국의 헬스케어 인프라 확충 등 시장에는 큰 성장 기회가 존재합니다. 또한, 맞춤형 의료에 대한 관심이 높아지고 유전자 시퀀싱, 분자 프로파일링과 같은 첨단 기술의 도입으로 향후 몇 년 동안 시장 성장을 위한 새로운 길이 열릴 것으로 예측됩니다.
본 조사의 주요 특징:
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 다음과 같은 매개 변수를 기반으로 세계 털세포 백혈병 시장의 주요 업체를 프로파일링합니다. 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과 및 전략.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 세계 털세포 백혈병 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 털세포 백혈병 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 털세포 백혈병 시장 : 치료법별, 2021년-2033년
제5장 세계의 털세포 백혈병 시장 : 투여 경로별, 2021년-2033년
제6장 세계의 털세포 백혈병 시장 : 연령층별, 2021년-2033년
제7장 세계의 털세포 백혈병 시장 : 성별 유형별, 2021년-2033년
제8장 세계의 털세포 백혈병 시장 : 최종사용자별, 2021년-2033년
제9장 세계의 털세포 백혈병 시장 : 유통 채널별, 2021년-2033년
제10장 세계의 털세포 백혈병 시장 : 지역별, 2021년-2033년
제11장 경쟁 구도
제12장 애널리스트의 제안
제13장 참고 문헌 및 조사 방법
LSH 26.06.12Hairy Cell Leukemia Market is estimated to be valued at USD 152.5 Mn in 2026 and is expected to reach USD 241.7 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 152.5 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.80% | 2033 Value Projection: | USD 241.7 Mn |
The global hairy cell leukemia market has witnessed significant growth in recent years, driven by increasing incidence rates, advancements in diagnostic techniques, and the development of innovative treatment options. Hairy cell leukemia is a rare, chronic, and slow-growing type of blood cancer that affects B lymphocytes, a type of white blood cell. The disease is characterized by the presence of abnormal hairy cells in the bone marrow, blood, and spleen, leading to symptoms such as fatigue, frequent infections, and an enlarged spleen. With the rising awareness about the disease and the availability of effective treatment options, the global hairy cell leukemia market is expected to experience substantial growth during the forecast period.
Market Dynamics:
The global hairy cell leukemia market is influenced by several factors, including drivers, restraints, and opportunities. One of the key drivers of the market is the increasing incidence of hairy cell leukemia worldwide, which can be attributed to factors such as genetic predisposition, environmental factors, and an aging population. Additionally, advancements in diagnostic techniques, such as flow cytometry and immunohistochemistry, have led to improved detection and diagnosis of the disease, further driving market growth. However, the market growth may be restrained by factors such as the high cost of treatment, limited awareness about the disease in developing regions, and the side effects associated with chemotherapy and targeted therapy. Despite these challenges, the market presents significant opportunities for growth, including the development of novel targeted therapies, increasing collaborations between pharmaceutical companies and research institutions, and the expansion of healthcare infrastructure in emerging economies. Moreover, the growing focus on personalized medicine and the adoption of advanced technologies, such as gene sequencing and molecular profiling, are expected to create new avenues for market growth in the coming years.
Key Features of the Study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global hairy cell leukemia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis, Roche, Bristol-Myers Squibb, Merck & Co., Amgen, Gilead Sciences, AbbVie, Celgene, Teva Pharmaceutical Industries, Takeda Pharmaceutical Company, Janssen Pharmaceuticals, Eli Lilly and Company, AstraZeneca, Sanofi, and Bayer AG
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global hairy cell leukemia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hairy cell leukemia market
Market Segmentation
- Therapy Type Insights (Revenue, USD Mn, 2021 - 2033)
- Chemotherapy
- Cladribine
- Pentostatin
- Targeted Therapy
- Ibrutinib
- Vemurafenib
- Moxetumomab Pasudotox
- Immunotherapy
- Monoclonal Antibodies
- Interferon Alpha
- Others Combination Regimens (e.g., Cladribine + Rituximab)
- Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
- Oral
- Parenteral
- Age Group Insights (Revenue, USD Mn, 2021 - 2033)
- Pediatric
- Adult
- Geriatric
- Gender Insights (Revenue, USD Mn, 2021 - 2033)
- Male
- Female
- End User Insights (Revenue, USD Mn, 2021 - 2033)
- Hospitals
- Oncology Clinics
- Cancer Research Organizations
- Ambulatory Care Centers
- Diagnostic Laboratories
- Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis
- Roche
- Bristol-Myers Squibb
- Merck & Co.
- Amgen
- Gilead Sciences
- AbbVie
- Celgene
- Teva Pharmaceutical Industries
- Takeda Pharmaceutical Company
- Janssen Pharmaceuticals
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Bayer AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Hairy Cell Leukemia Market, By Therapy Type
- Global Hairy Cell Leukemia Market, By Route of Administration
- Global Hairy Cell Leukemia Market, By Age Group
- Global Hairy Cell Leukemia Market, By Gender
- Global Hairy Cell Leukemia Market, By End User
- Global Hairy Cell Leukemia Market, By Distribution Channel
- Global Hairy Cell Leukemia Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Hairy Cell Leukemia Market, By Therapy Type, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Cladribine
- Pentostatin
- Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Ibrutinib
- Vemurafenib
- Moxetumomab Pasudotox
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Monoclonal Antibodies
- Interferon Alpha
- Others Combination Regimens (e.g., Cladribine + Rituximab)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
5. Global Hairy Cell Leukemia Market, By Route of Administration, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
6. Global Hairy Cell Leukemia Market, By Age Group, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
7. Global Hairy Cell Leukemia Market, By Gender, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
8. Global Hairy Cell Leukemia Market, By End User, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Oncology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Cancer Research Organizations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Ambulatory Care Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
9. Global Hairy Cell Leukemia Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
10. Global Hairy Cell Leukemia Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Therapy Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Celgene
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
